Naing and colleagues found that pegylated IL-10, also known as Pegilodecakin, has the potential to systematically stimulate immune responses in individuals with cancer, notably improving the function of CD8+ T cells and encouraging the expansion of polyclonal T cells (17). Here, CD8A is linked to cancer.